glp-1 obesity drug news today As drugs continue to gain popularity for weight loss, a lesser-known side effect is drawing attention from podiatrists: “Ozempic feet.” Story🔗below Study predicts 16 new obesity
Description
Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP
J.et al (2022)
A., Singh, L., Singh, G
The method for developing the summary of findings (SoF) table and determining the quality of evidence as high, moderate, low, or very low has been described elsewhere [19]
Interestingly, a new version of GLP-1s known as tirzepatide (Mounjaro) may be more effective than semaglutide
Lakhani M, Kwan ATH, Mihalache A, et al
